{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T12:55:33Z","timestamp":1765544133581,"version":"3.48.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008967","name":"Philipps-Universit\u00e4t Marburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008967","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00066-025-02458-0","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:00:21Z","timestamp":1757415621000},"page":"1317-1319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hat die SBRT beim nodalen Oligorezidiv des Prostatakarzinoms noch einen Stellenwert oder ist die ENRT mit ADT der neue Standard?","Does SBRT still have a\u00a0role to play in nodal oligorecurrent prostate cancer or is ENRT with ADT the new standard?"],"prefix":"10.1007","volume":"201","author":[{"given":"Niklas","family":"Recknagel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Adeberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"issue":"6","key":"2458_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","volume":"26","author":"P Ost","year":"2025","unstructured":"Ost\u00a0P et\u00a0al (2025) Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V\u2011STORM): a\u00a0phase\u00a02, open-label, randomised controlled trial. Lancet Oncol 26(6):695\u2013706","journal-title":"Lancet Oncol"},{"key":"2458_CR2","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF): S3-Leitlinie Prostatakarzinom, Langversion 6.0, 2021, AWMF Registernummer: 043\/022OL, http:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/prostatakarzinom\/ (abgerufen am: 15.07.2025)"},{"key":"2458_CR3","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Prostate Cancer. Version 2.2024"},{"issue":"12","key":"2458_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-095560","volume":"14","author":"F Slevin","year":"2024","unstructured":"Slevin\u00a0F et\u00a0al (2024) Pelvis Or Involved Node Treatment: Eradicating Recurrence in Prostate Cancer (POINTER-PC) \u2013 study protocol paper for a phase III multicentre, open-label randomised controlled trial. BMJ Open 14(12):e095560","journal-title":"BMJ Open"},{"key":"2458_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.640467","volume":"11","author":"S Kirste","year":"2021","unstructured":"Kirste\u00a0S et\u00a0al (2021) Combining (68)Ga-PSMA-PET\/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A\u00a0Retrospective Multicenter Study. Front Oncol 11:640467","journal-title":"Front Oncol"},{"issue":"11","key":"2458_CR6","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","volume":"7","author":"TA Hope","year":"2021","unstructured":"Hope\u00a0TA et\u00a0al (2021) Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A\u00a0Multicenter Prospective Phase\u00a03 Imaging Trial. JAMA Oncol 7(11):1635\u20131642","journal-title":"JAMA Oncol"},{"issue":"3","key":"2458_CR7","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","volume":"26","author":"G Marvaso","year":"2025","unstructured":"Marvaso\u00a0G et\u00a0al (2025) ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a\u00a0randomised, open-label, phase\u00a02 clinical trial. Lancet Oncol 26(3):300\u2013311","journal-title":"Lancet Oncol"},{"issue":"10024","key":"2458_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James\u00a0ND et\u00a0al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024):1163\u20131177","journal-title":"Lancet"},{"issue":"15","key":"2458_CR9","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1200\/JCO.2007.14.9021","volume":"26","author":"EM Horwitz","year":"2008","unstructured":"Horwitz\u00a0EM et\u00a0al (2008) Ten-year follow-up of radiation therapy oncology group protocol 92-02: a\u00a0phase\u00a0III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J\u00a0Clin Oncol 26(15):2497\u20132504","journal-title":"J Clin Oncol"},{"issue":"24","key":"2458_CR10","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","volume":"360","author":"M Bolla","year":"2009","unstructured":"Bolla\u00a0M et\u00a0al (2009) Duration of Androgen Suppression in the Treatment of Prostate Cancer. N\u00a0Engl J Med 360(24):2516\u20132527","journal-title":"N Engl J Med"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02458-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-025-02458-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02458-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T12:52:28Z","timestamp":1765543948000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-025-02458-0"}},"subtitle":["Eine Interpretation des PEACE V-STORM Trials","An interpretation of the PEACE V-STORM trial"],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2458"],"URL":"https:\/\/doi.org\/10.1007\/s00066-025-02458-0","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"type":"print","value":"0179-7158"},{"type":"electronic","value":"1439-099X"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"2 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.\u00a0Recknagel und S.\u00a0Adeberg geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}